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Background: We determined the feasibility, safety, and short-term efficacy of
bronchoscopic placement of a one-way endobronchial valve in selected bron-
chopulmonary segments as an alternative to surgical lung volume reduction.
Methods: A total of 21 patients with incapacitating emphysema who underwent
this procedure were studied. All patients had placement of the endobronchial
valves into the most emphysematous lung segments. We recorded any major
complications or deaths attributed to the procedure and analyzed (1) improve-
ments in the spirometric and functional parameters and quality of life and (2) the
radiologic changes compared with the baseline data at 30 and 90 days.
Results: A total of 20 patients had complete follow-up data. There was no mortality
in the group studied. The forced expiratory volume at 1 second, forced expiratory
volume at 1 second (percentage of predicted), forced vital capacity, and forced vital
capacity (percentage of predicted) all improved significantly at 90 days (0.73 0.26
L vs 0.92 0.34 L [P .009]; 33.3% 11.9% vs 42.2% 15.0% [P .006]; 1.94
 0.62 L vs 2.25  0.61 L [P  .015]; and 63.3%  17.6% vs 73.9%  17.1% [P
 .012], respectively). The 6-minute walking distance improved at 30 and 90 days
(251.6  100.2 m vs 306.3  112.3 m and 322.3  129.7 m; P  .012 and P 
.003). The results of the 36-Item Short-Form Health Survey and the St George
Respiratory Questionnaire showed significant improvements at 90 days. The Med-
ical Research Council dyspnea grade also improved significantly at 30 and at 90
days (P  .006 and P  .003, respectively).
Conclusions: Endobronchial valve placement is a safe procedure, with significant
short-term improvements in functional status, quality of life, and relief of dyspnea
in selected patients with emphysema. A larger study with long-term follow-up is
therefore warranted.
Emphysema continues to be a major cause of morbidity and mortalityin developed countries. The disease affects approximately 2 millionpeople alone in the United States, with associated costs of US$2.5billion annually, and nearly 17,000 deaths each year are attributed toemphysema.1 Despite the controversies, lung volume reduction sur-gery (LVRS) has been shown to be beneficial to selected patients
with end-stage emphysema when medical therapy has failed.2,3 The operation was
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popularized by Cooper and associates4 in the early 1990s.
The principle of LVRS is that removal of the most diseased
parts of the hyperinflated lungs helps to restore the chest
wall and diaphragmatic mechanics in respiration.
Nonetheless, the trauma of operation (even with the
thoracoscopic approach) means that only a relatively small
percentage of patients with severe emphysema would ben-
efit from such treatment. Patients with very low forced
expiratory volume at 1 second (FEV1) and either homoge-
neous emphysema or a very low carbon monoxide–diffus-
ing capacity (DLCO) are at high risk of death after LVRS,5
and the most recent published data have also indicated that
patients with non–upper-lobe disease have a higher opera-
tive mortality when undergoing operation.6
Recently, several devices have emerged, based on the
bronchoscopic approach, as possible alternatives to LVRS.
The most studied of these is the Endobronchial Valve (Em-
phasys Medical Inc, Redwood City, Calif). By placing these
one-way endobronchial valves (EBV) bronchoscopically
into the most emphysematous lung segments, air is pre-
vented from entering into the isolated segments, but distal
bronchial secretions are allowed to escape (Figure 1). The
net result is induced atelectasis of the most emphysematous
segments and redirection of air flow (or ventilation) to the
least emphysematous lung to reproduce the clinical benefits
of LVRS without exposing the patients to the risks associ-
ated with a major operation.
Fann and colleagues7 conducted an animal experiment
with EBV in which 9 sheep underwent placement of 40
valves in the bronchopulmonary segments. The animals
were serially killed from 1 week to 6 months. Both lungs
with the trachea were explanted en bloc and then fixed in
formalin. All but 3 valve devices were structurally intact
and well seated in the bronchial lumen. The 3 valves were
coughed out. Evidence of gross collapse was seen distal to
34 (85%) of 40 valve devices on thoracotomy, whereas
histologic atelectasis was evident in lung segments distal to
36 devices (90%) after fixation.
Toma and colleagues8 were the first to report on the
clinical experience of this device in a pilot study involving
8 patients with severe emphysema. All had unilateral im-
plantation of the one-way valves. There were no deaths, and
pneumothorax was the only reported complication. There
was an improvement of the median FEV1 at follow-up after
4 weeks. Likewise, Snell and colleagues9 reported on 10
patients and showed improvement in gas transfer. These
studies paved the way for a larger clinical study on safety
and feasibility, which forms the basis of this report.
Patients and Methods
We conducted a prospective, nonrandomized, single-center longi-
tudinal cohort study to evaluate the efficacy and safety of endo-
scopic LVRS by placement of EBVs via rigid bronchoscopy.
During the 12-month period from April 2002 to March 2003, a
total of 62 patients with incapacitating emphysema who were
receiving maximal medical therapy were initially recruited for
evaluation. Only 21 patients were finally included in the study on
the basis of our selection criteria (Table 1).
Each patient was clinically assessed jointly by the principal
investigator (A.P.C.Y.) and a designated team of thoracic sur-
geons, pulmonologists, and a radiologist. All patients had a com-
puted tomographic (CT) scan of the thorax and a ventilation-
perfusion (V˙ /Q˙ ) scan before and then 30 and 90 days after the
placement of these valves. A single-detector spiral CT scanner
(HiSpeed Advantage RP Scanner; GE Medical Systems, Milwau-
kee, Wis) with collimation of 5 mm and pitch at 2:1 was used. For
the V˙ /Q˙ scan, 40 mCi of technetium Tc 99m diethylenetriamine
pentaacetic acid aerosol was used for the ventilation scan, whereas
5 mCi of 99mTc-labeled macroaggregated albumin was used for the
Figure 1. A, Endobronchial valve (Emphasys, Redwood City, Calif). B, Bronchoscopic view showing the endobron-
chial valve after placement in the target bronchial segment (black arrow).
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perfusion scan. The signals were then acquired by using a dual-
head gamma camera equipped with a low-energy parallel hole
general purpose collimator. The energy was set at 140 keV with a
20% symmetrical window, and the images were stored in the
format of a 128  128 matrix. All the radiologic examinations
were then reviewed by 1 radiologist (T.K.Y.).
Full pulmonary function tests, including arterial blood gas
measurements, were obtained for each patient. Transthoracic echo-
cardiography was performed to assess right heart function and to
rule out pulmonary hypertension. Baseline 6-minute walking dis-
tance (6MWD) was recorded as an assessment of exercise toler-
ance. Quality-of-life assessment by using the 36-Item Short-Form
Health Survey (SF-36) and the St George Respiratory Question-
naire (both validated for Chinese patients)10,11 was undertaken.
The degree of dyspnea experienced by each patient was measured
by the Medical Research Council dyspnea grade.
The primary end point was any major complication or death
attributed to the procedure within the study period. The secondary
end points of the study were related to the degree of improvement
in the lung function, 6MWD, and health-related quality of life
(HRQOL) when compared with the baseline data at 30 and 90
days. The results were analyzed with SPSS for Windows version
11.0 (SPSS Inc, Chicago, Ill).
The protocol was formally approved by the University ethical
committee (equivalent to the institutional review board). Nearly all
these patients (except 1 with pleurodesis [patient 7] and another
who already had LVRS [patient 17]) were candidates for LVRS.
All patients knew and understood LVRS. Our procedure was
offered to them as a new, investigational, and possibly alternative
procedure. They understood that LVRS remained an option if this
failed. All patients were given a choice of therapy, but none
declined this procedure when it was offered. Informed consent was
obtained from each patient.
Procedure
The procedure was performed in the operating room under total
intravenous anesthesia with 2,6-dispropylphenol or propofol
(Diprivan). The patient was kept in assisted spontaneous ventila-
tion throughout the procedure and placed supine with the head
slightly extended. The target areas for EBV placement were pre-
viously selected primarily on the basis of V˙ /Q˙ scan in conjunction
with pulmonary CT scan. A ventilating rigid bronchoscope with a
Hopkins telescope (Efer-Dumon Bronchoscope; Efer, La Ciotat,
France) was introduced through the mouth into the airway and was
then connected to a 3-chip camera system (Stryker 784; Stryker,
Kalamazoo, Mich) with the tip of the bronchoscope positioned at
the target lobar orifice (usually one of the upper lobes). The rigid
telescope was then exchanged for a flexible bronchoscope, which
passed through the rigid bronchoscope to reach each of the target
segmental bronchial orifices. A guide wire (0.035-inch external
diameter) was threaded through the instrument channel of the
flexible bronchoscope into the segmental bronchus. With a mod-
ified Seldinger technique, a carrier loaded with the EBV of the
appropriate size (3 diameter sizes of 4.0-5.5 mm, 5.0-7.0 mm, and
6.5-8.5 mm are available) was placed at the segmental bronchial
orifice, and the EBV was deployed. The entire procedure was
visually monitored by the video bronchoscope. Depending on the
exact morbid anatomy, 1 or more valves were placed in the
endobronchial tree. For some patients, some segments appeared to
be more affected than others within the same lobe (especially for
the lower lobe). Overall, 28 lobes were targeted in the 20 patients.
Complete lobar occlusion was undertaken in 16 lobes, and 45
valves were placed (2.81 valves per lobe targeted). Incomplete
lobar occlusion was performed in the remaining 12 lobes, and 32
valves were used (2.67 valves per lobe targeted). We placed the
valves only in the most affected segments, rather than indiscrim-
inately in all segments of the lobe. In 1 patient (patient 17), we
were unable to place the valve at the apical segment of the right
upper lobe because of technical reasons—the guide wire flipped
out of the target segment every time as the introducer was ad-
vanced.
Postoperative Care and Follow-up
Chest radiographs and arterial blood gas measurements were per-
formed after surgery, and noninvasive arterial oxygen saturation
was continuously monitored. The patients were encouraged to
cough (assisted by physiotherapists) to clear any mucus or air
remaining behind the valve. All patients received a prophylactic
10-day total course of antibiotics (amoxicillin/clavulanate or rox-
ithromycin), as well as inhaled salbutamol and ipratropium bro-
mide. At the time of discharge, patients were given a wallet card
that can be presented to health-care providers, with a brief expla-
nation of the procedure and contact information for the enrolling
physician. Participants in the study were invited to contact the
hospital for any advice or assistance at any time after the study.
Follow-up was weekly for the first month and then twice monthly
thereafter, with specific investigations performed at different time
points.
Statistical Analysis
All descriptive statistics were expressed as mean  SD for con-
tinuous variables and as median (range) for ordinal data. Paired
2-tailed t tests were used to analyze quantitative continuous vari-
ables comparing the means for the group. Repeated-measures
analysis of variance was performed to compare the means of the
variables that had been measured at more than 1 occasion for each
individual at the 3 time points (before the procedure and 30 and 90
days after the procedure). Bonferroni correction was used to adjust
TABLE 1. Inclusion and exclusion criteria of the EBV study
Inclusion criteria
Symptomatic emphysema
Age 50 to 80 y
Patient has shortness of breath on routine daily activities
despite maximal medical therapy
Heterogeneous disease on pulmonary CT and V˙/Q˙ scan
Exclusion criteria
FEV1 20% of predicted value
Hypercapnea with PaCO2 55 mm Hg
Diffusion capacity 25% of predicted value
Pulmonary hypertension
Evidence of active pulmonary infection
Patient cannot or will not comply with follow-up
investigations
EBV, Endobronchial valve; CT, computed tomographic; V˙/Q˙, ventilation-
perfusion; FEV1, forced expiratory volume in 1 second.
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the observed significance level when multiple comparisons of the
means were made. The Friedman test and the Wilcoxon signed-
rank test were used for ordinal variables. All statistical analysis
was performed with SPSS for Windows version 11.0.
Results
A total of 21 patients underwent the procedure described
previously. One patient (patient 2) who had some clinical
improvement but declined follow-up investigations was ex-
cluded from the analysis. For the remaining 20 patients (1
woman only), the mean age was 68.55 7.40 years. All but
1 patient were ex-smokers, with a mean pack-years history
of 49.5  25.58. Bilateral insertions of the EBV were
undertaken in 8 of the 20 patients. Two of the patients
(patients 13 and 19) were admitted overnight to the inten-
sive care unit for observation because of mild postoperative
carbon dioxide retention. The third patient (patient 5) was
admitted 8 days after the initial operation because of devel-
opment of bilateral pneumothorax that required a second
operation for resection of a rupture bulla on one side (not in
the stented segment). None of the patients required mechan-
ical ventilation during their intensive care unit stay. The
mean hospital stay was 5.60  6.37 days. There was no
procedure-related death. Six patients experienced complica-
tions during the immediate postoperative period; pneumo-
thorax was the most common complication (Table 2). Chest
drains were inserted in all the patients in whom large
pneumothoraces developed (patients 5, 11, and 13). All
patients but 1 showed no active air leak, suggesting that the
pneumothorax was caused by induced collapse of the lung
segments (Figure 2). Bilateral pneumothoraces developed in
1 patient (patient 5), who, after placement of EBVs to both
of the upper lobes, required video-assisted thorascopic sur-
gery exploration and excision of a ruptured bulla in the left
lower lobe. All the pneumothoraces resolved by the
1-month follow-up. Bronchoscopic assessment was under-
taken for the first 6 patients at 1 month, and all demonstrated
functioning valves with no evidence of displacement. Be-
cause the compliance for this particular follow-up procedure
was poor, the procedure was not performed for the remain-
ing patients.
Spirometric and Functional Assessments
There were significant improvements in the mean value of
FEV1 (percentage of predicted) and forced vital capacity
(percentage of predicted) at each follow-up time point (Ta-
ble 3). The mean value of FEV1 was improved by 15% at 30
days (0.73  0.26 L vs 0.84  0.27 L) and by 26% at 90
days (0.73  0.26 L vs 0.92  0.34 L), and this improve-
ment was significant at 90 days (P .009). The mean value
of forced vital capacity also increased and became statisti-
cally significant at 90 days (1.94  0.62 L vs 2.25  0.61
L; P .015). Although there was a trend of improvement in
the mean DLCO value by 15% and 13% at 30 and 90 days,
respectively, after the procedure, these changes were not
statistically significant. Likewise, lung volumes (measured
by body plethysmography) demonstrated a reduction of the
residual volume and the total lung capacity, but the results
did not reach statistical significance. Exercise tolerance as
measured by the 6MWD test demonstrated an improvement
of 22% at 30 days (251.6  100.2 m vs 306.3  112.3 m;
P  .012) and by 28% at 90 days (251.6  100.2 m vs
322.3  129.7 m; P  .003) when compared with baseline.
HRQOL Assessments
The baseline data of the SF-36 health survey (Appendix 1)
suggested an impairment of HRQOL. The lowest scores
were recorded in physical function (30.5  16.6), general
health (32.5 15.0), and role limitation (36.8 41.1; Table
4). Seven of 9 domains of the SF-36 health survey showed
an improvement at 30 days and again at 90 days; physical
functioning, change in health, general health, and vitality
improved significantly after the procedure at 30 days (P 
.001, .001, .001, and .015, respectively), and the phys-
ical functioning and change in health domains produced a
sustainable improvement at 90 days (P  .003 and P 
.001, respectively).
TABLE 2. Patient characteristics (20 cases)
Patient
no.*
No.
valves
Position
of valves
Postprocedure
length of stay
(d) Perioperative complications
1 2 RLL 1 None
3 7 RUL, LUL 3 Right pneumothorax
4 2 RLL 3 None
5 5 RUL, LUL 29 Bilateral pneumothoraces
CO2 retention
6 6 RLL, LLL 5 None
7 4 RUL 5 None
8 6 LLL 2 None
9 6 RUL, LUL 10 Sputum retention
10 4 LUL 14 None
11 4 RUL 5 Right pneumothorax
12 6 RUL, LUL 2 None
13 4 LLL 3 Left pneumothorax, CO2
retention
14 4 LLL 2 None
15 3 RUL 1 None
16 2 LUL 2 None
17 3 RUL 5 None
18 3 RLL 3 None
19 3 RUL, LUL 3 Bronchospasm, CO2
retention
20 8 RUL, LUL 7 None
21 5 RUL, LLL 7 None
RLL, Right lower lobe; RUL, right upper lobe; LUL, left upper lobe; RLL, right
lower lobe.
*Patient 2 declined follow-up investigations and so was excluded from the
study.
Yim et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 127, Number 6 1567
G
TS
As for the analysis of the St George Respiratory Ques-
tionnaire results (Appendix 2), comparisons of data were
not possible before 3 months, because some of the assess-
ments within the questionnaire cannot be fully answered
until then. The baseline values suggested a generalized
impairment of patients’ quality of life; the worst result
obtained was in the activity score (78.9  16.4). Statisti-
cally significant improvements in all 4 domains measured
were demonstrated at 90 days. Overall, 85% of the group
that reported an improvement of dyspnea at 30 days after
the procedure with the Medical Research Council dyspnea
grade (Appendix 3) measurement demonstrated an improve-
ment at 30 and 90 days (P  .006 and .003, respectively),
thus indicating a significant reduction in the symptoms.
Radiologic Assessments
EBVs were placed in 28 pulmonary lobes in 20 patients
(Table 2). A total of 17 patients with 23 targeted lobes had
complete CT evaluation at each follow-up for the degree of
induced collapse. The degree of collapse of the respective
lobes seen in the CT scans was categorized arbitrarily into
4 grades: grade 0 (0% collapse), grade 1 (25% collapse),
Figure 2. A, Baseline chest radiograph of patient 3 showing hyperinflated lung fields and a flattened diaphragm
compatible with emphysema. B, Chest radiograph of the same patient showing collapse of the right upper lobe and
an apical pneumothorax (white arrows) at postoperative day 1 after EBV placement in both upper lobes. C, Chest
radiograph of the same patient showing progressive collapse of the right upper lobe (without pneumothorax) 1
month after placement of the EBVs.
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TABLE 4. Health-related quality of life changes before and after Emphasys bronchial valve placement
Variable Before procedure At 1 mo At 3 mo
Repeated-measures
analysis
P value (with Bonferroni
correction)
P value
Linear
trend
Comparison
between
before
procedure
and at 1 mo
Comparison
between
before
procedure
and at 3 mo
SF-36*
Physical functioning 30.5 16.6 57.5 27.0 63.1 32.0 .001 .001 .001 .003
Role limitation due to
physical problems
36.8 41.1 65.6 40.7 56.9 46.8 .090 .095 .288 .378
Bodily pain 94.7 14.7 89.8 20.6 92.9 20.8 .189 .808 1.725 1.152
General health 32.5 15.0 61.9 21.6 44.7 26.0 .001 .012 .001 .243
Vitality 44.2 21.0 64.4 14.8 60.0 27.2 .005 .013 .015 .357
Social functioning 48.7 30.6 69.5 26.2 71.5 39.3 .004 .002 .123 .123
Role limitation due to
emotional problems
70.2 44.3 85.4 32.1 70.4 45.6 .400 .348 .654 2.415
Mental health 69.3 17.4 79.5 14.5 76.4 22.4 .042 .042 .114 .822
Change in health 38.9 17.0 85.0 21.3 74.4 28.9 .001 .001 .001 .001
SGRQ†
Symptoms score 52.8 17.1 N/A 39.2 27.4 N/A N/A .025
Activity score 78.9 16.4 N/A 52.8 28.2 N/A N/A .001
Impact score 56.7 20.7 N/A 31.8 26.4 N/A N/A .014
Total score 62.7 14.2 N/A 39.3 24.4 N/A N/A .003
MRC grade‡ 3 (2–5) 2 (1–5) 1 (1–4) N/A .006 .003
Data are presented as mean  SD or median (range). N/A, Not available.
*The 36-Item Short-Form Health Survey (SF-36) scores range from 0 to 100. Higher scores represent higher levels of functioning/quality of life and fewer
symptoms.
†St George Respiratory Questionnaire (SGRQ) scores range from 0 to 100. Lower scores represent higher levels of functioning/quality of life and fewer
symptoms.
‡Medical Research Council (MRC) grades range from 1 to 5. Lower scores represent fewer symptoms.
TABLE 3. Spirometric functional changes before and after Emphasys bronchial valve placement
Variable Before procedure At 1 mo At 3 mo
Repeated-
measures analysis
P value (with Bonferroni
correction)
P value
Linear
trend
Comparison
between
before
procedure
and at 1 mo
Comparison
between
before
procedure
and at 3 mo
Pulmonary function
FEV1 (L) 0.73 0.26 0.84 0.27 0.92 0.34 .003 .006 .075 .009
FEV1 (% predicted) 33.3 11.9 38.8 13.2 42.2 15.0 .004 .004 .045 .006
FVC (L) 1.94 0.62 2.12 0.47 2.25 0.61 .002 .002 .06 .015
FVC (% predicted) 63.3 17.6 70.5 14.3 73.9 17.1 .001 .002 .021 .012
TLC (L) 7.03 1.60 6.50 1.77 6.58 1.48 .895 .930 1.041 1.446
TLC (% predicted) 146.4 30.8 144.6 60.9 141.1 40.4 .860 .869 1.263 2.16
DLCO (mL/min/mm Hg) 8.00 4.13 9.18 4.12 9.06 4.09 .504 .339 1.677 1.179
DLCO (% predicted) 50.8 21.0 59.6 22.0 60.6 24.4 .157 .133 .54 .426
RV (L) 4.98 1.49 4.85 1.97 4.43 1.43 .851 .770 1.065 1.14
RV (% predicted) 368.9 127.4 350.9 191.2 326.7 133.9 .876 .987 1.332 1.539
RV/TLC 0.71 0.12 0.72 0.13 0.67 0.10 .699 .565 1.392 .885
Exercise tolerance
6MWD (m) 251.6 100.2 306.3 112.3 322.3 129.7 .001 .001 .012 .003
Data are presented as mean  SD. FEV1, Forced expiratory volume in 1 second; FVC, forced vital capacity; TLC, total lung capacity; DLCO, carbon
monoxide– diffusing capacity; RV, residual volume; 6MWD, 6-min walking distance.
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grade 2 (25% to 75% collapse), and grade 3 (75% col-
lapse). It is interesting to note that only 10 (43%) of the 23
lobes showed some degree of collapse after the placement
of the EBVs during the entire follow-up period. Six of these
10 lobes remained unchanged throughout the follow-up
period, whereas 2 lobes showed mild re-expansion and the
remaining 2 showed no collapse at all in the first month but
had a delayed collapse at the third month (Table 5). For
those 13 pulmonary lobes that showed no collapse through-
out the 3-month follow-up period, the serial V˙ /Q˙ scinti-
graphic findings of the respective lobes also remained static.
Discussion
The concept of nonresectional lung volume reduction has
emerged recently, and new devices and strategies were
developed to achieve endoscopic lung volume reduction
without the need for open operation. These include induced
atelectasis by using endobronchial sealants, occluders, or
valves and creation of extra-anatomic tracts within the ma-
jor airway to facilitate expiratory airflow.
However, most of the new devices and strategies men-
tioned previously remain in the animal experimentation
phase, and very few have come to clinical study. Early work
in the area of internal isolation of lung segments by Sa-
banathan and associates12 with 2 different designs of bron-
chial blockers (silicone balloons and occluded stents) in
human subjects demonstrated improvement of symptoms in
5 of 8 patients. However, prosthesis migration, expectora-
tion, and development of pneumonia limited the application
of this approach. On the basis of information drawn from
that study and results from animal models of bronchoscopic
lung volume reduction, an ideal endobronchial device
should therefore have the following qualities: (1) it should
be effective in achieving and sustaining lung volume reduc-
tion, (2) the results should be reproducible, (3) the device
should preferably be deployable by using a flexible bron-
choscope with the patient under local anesthesia, (4) the
device should be easily removable by using a flexible bron-
choscope, (5) the design of the device should allow no
migration or displacement in the airway, (6) bronchial se-
cretions should be allowed to escape, and (7) there should
be no pulmonary infection due to sputum retention. A full
discussion of the available prototype devices is beyond the
scope of this article, and interested readers are referred to
the literature regarding the umbrella valve (Spiration, Inc,
Redmond, Wash),13 various types of endobronchial block-
ers, and sealant.14-16
An alternative concept of creating extra-anatomic tracts
was initially suggested by Macklem17 on the basis of the
theory that the formation of extra pathways between the
lung and the chest wall would allow escape of trapped air
and thus improve the expiratory flow. This concept was
modified, and extra-anatomic tracts can now be created
through the bronchoscope between the major airway and the
emphysematous lung parenchyma by using a radiofre-
quency probe (Broncus Technologies, Mountain View,
Calif), and stents are then put in place in these iatrogenic
tracts to prevent them from collapsing. Lausberg and col-
leagues18 from the Washington University School of Med-
icine reported a significant improvement of the FEV1 after
nonanatomic tracts were created by using specific radiofre-
quency probes, followed by placement of expanding stents
into each of the passageways by using human emphysema-
tous lungs removed from the time of transplantation. The
use of intraoperative endobronchial Doppler imaging is
important in guiding the procedure and avoiding vessel
perforation in a clinical study.19
The data from this study indicated that bronchoscopic
placement of the EBVs is a safe procedure, and significant
improvements were seen in pulmonary function, exercise
tolerance, dyspnea scores, and HRQOL. Furthermore, ad-
mission to the intensive care unit is not mandatory, even in
these high-risk patients. Only 3 of 20 patients needed ad-
mission to the intensive care unit: 2 for overnight observa-
tion because of carbon dioxide retention (but did not require
mechanical ventilation) and 1 with postoperative pneumo-
thorax (this patient eventually required another operation, as
stated previously).
The exact mechanism for the pneumothorax remains
unclear. It is almost certainly due to acute lung volume loss
secondary to valve placement, but it begs the question why
the remaining lung did not rise up to occupy the space.
Pleural adhesion is a possible explanation but may be inad-
equate to account for the frequency of our observation. We
do know, however, that there was no buildup of possible
pressure in the pneumothorax space, because there was no
air leak from the chest drain and because applying gentle
suction did not completely resolve the pneumothorax.
Because no pneumonia was identified during the fol-
low-up period, this suggests that bronchial secretion is be-
ing cleared in these isolated segments. It is not entirely
unexpected that induced lobar collapse was evident on CT
scans in only 10 of the 20 patients at 90 days (Figure 3). One
explanation is that excess collateral airflow occurred in the
emphysematous lungs20 and prevented the collapse of the
target zones in some of our patients. Similar results were
TABLE 5. Summary of CT findings after Emphasys bron-
chial valve placement
Grade
No. of lobes
at 1 mo
No. of lobes
at 3 mo
Grade 0 (0% collapse) 15 13
Grade 1 (25% collapse) 3 6
Grade 2 (25% to 75% collapse) 1 0
Grade 3 (75% collapse) 4 4
CT, Computed tomography.
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also seen in the pilot study conducted by Toma and col-
leagues,8 in which lobar collapse was evident in only 50%
of the patients by using the same valve. This would have
explained the fact that neither residual volume nor total lung
capacity showed a significant decrease in our study. Even
though segmental collapse is not always present, there is
Figure 3. Baseline CT scan (left) and CT scan of the same patient at 1 month (right) after the procedure, showing
collapse of the target segments (mainly the apical segment of the right upper lobe; arrows.) The 3-month result was
similar to the image at 1 month (not shown).
Figure 4. Baseline V˙/Q˙ scan (top) of patient 3 showing a heterogeneous emphysema pattern. A V˙/Q˙ scan of the
same patient at 3 months after EBV placement (bottom) shows an improvement of the ventilation (narrow arrows)
and a corresponding improvement of the ventilation (broad arrows) when compared with baseline.
Yim et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 127, Number 6 1571
G
TS
nonetheless a trend of improvement in the DLCO. This
observation could be explained by airflow being redirected
to the relatively healthier portions of the lungs by these
one-way valves and hence reducing the V˙ /Q˙ mismatch
(Figure 4). More study is definitely needed in this area.
Three-dimensional CT scans provide a very accurate
estimate of lung volume,21 and with thin CT thorax slices
(collimation of 5 mm), good follow-up images can provide
an estimation of the degree of emphysema in different
segments of the lungs. Follow-up thorax CT at both at 30
and 90 days is essential, because there are cases of re-
expansion and delayed collapse.
Radiologically, V˙ /Q˙ scan does not prove to be useful in
the follow-up of these patients, because the findings are
variable and the scan did not pick up subtle collapse in the
lobes. Xenon scan with bronchial blockers may be helpful in
delineating the collateral air drift between the segments, and
this may help in selecting future patients for the placement
of EBVs. Further study on this is currently under way.
In conclusion, this is the first detailed report on the
feasibility, short-term outcome, and improvement of
HRQOL after EBV placement for emphysema treatment.
Our results suggest that a larger multicenter study with
long-term follow-up is warranted. Such a trial—the Inter-
national Endobronchial Valve for Emphysema Palliation
Registry—is currently being organized.
The authors thank Albert Cheung from The Centre for Epide-
miology and Biostatistics, The Chinese University of Hong Kong,
for his advice on and assistance with statistics.
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Appendix 1: Nine Domains of the Chinese SF-36
Survey Questionnaire
1. Physical functioning: assesses the individual’s ability to
perform all physical activities, including events of daily
living. A low score means more limitations.
2. Role-physical: assesses the individual’s lack of physical
ability to fulfill his or her daily roles. A low score means
there is a problem.
3. Bodily pain: assesses the results of physical activities. A
low score means severe pain.
4. General health: evaluates the personal assessment of phys-
ical and mental health. A low score means the person sees
his or her health as poor.
5. Vitality: assesses the person’s physical and mental well-
being. A low score means that the individual feels tired and
worn out.
6. Social functioning: evaluates the disability to conduct social
interaction. A low score suggests extreme limitation.
7. Role-emotional: assesses mental disability. A low score
means that a person is unable to fulfill his or her roles
because of emotional problems.
8. Mental health: assesses the person’s mental function. A low
score indicates that an individual feels nervous and de-
pressed most of the time.
9. Change in health: assesses the individual’s perception of
improvement in health. A low score would indicate that the
person feels that there is no improvement in his or her health
status.
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Appendix 2: St George Respiratory Questionnaire–
Hong Kong
1. Symptoms: assesses the component of respiratory symp-
toms (their frequency and severity).
2. Activity: relates to the activities that cause or are limited by
breathlessness.
3. Impact: concerns aspects of social functioning and psycho-
logical disturbances resulting from the disease.
4. Total score: summarizes the overall impairment and is ex-
pressed as a percentage, where 100% is the worst possible
outcome and 0% indicates the opposite.
Appendix 3: Medical Research Council
Grades—Degree of Dyspnea
Grade 1: not troubled with breathlessness, except on strenuous
exertion.
Grade 2: short of breath when hurrying on the level or walking up
a slight hill.
Grade 3: patient walks more slowly than most people on the level.
Grade 4: patient has to stop for breathing after walking for
approximately 100 yards on the level.
Grade 5: too breathless to leave home or feeling breathless after
undressing.
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